Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

“It’s a whole generation and a whole generational change.” The overarching theme of the report is that pharma marketers need to continuously evolve their strategies to keep pace with changing consumer ...

primarily focusing on BioMarin Pharmaceutical’s strategic initiatives and growth potential. The company has been undergoing significant changes under its new leadership, aiming to enhance ...

Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto) today ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

A drug developer in Research Triangle Park has made more changes to its leadership team ... commercial officer and Christiana Cioffi as chief strategy officer. These appointments are a critical ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

I don’t foresee major policy-driven changes impacting Indian pharma exports to the US ... Will the act influence Cipla’s manufacturing strategy? The trend of manufacturing closer to the US market ...

Major Changes To Indonesia’s New Patent Law. Legal News and Analysis - Indonesia - Intellectual Property - Conventus Law ...

Could the topline be a warning sign for Trump? Sure. After all, J. ANN SELZER’s poll is the gold standard. And, as our in-house polling expert Steve Shepard writes, her last survey in 2020 ended up ...

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to ... Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd ...